Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 July 2024
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 August 2022
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) (TA701)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 May 2021
Baricitinib for treating moderate to severe atopic dermatitis (TA681)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 March 2021
Dupilumab for treating moderate to severe atopic dermatitis (TA534)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 August 2018
Alitretinoin for the treatment of severe chronic hand eczema (TA177)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 August 2009
Frequency of application of topical corticosteroids for atopic eczema (TA81)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 August 2004
Tacrolimus and pimecrolimus for atopic eczema (TA82)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 August 2004
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 May 2025
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TS ID 10639]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for children with severe atopic dermatitis [TS ID 10434]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Delgocitinib for treating moderate to severe chronic hand eczema ID6408Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC